{"id":816179,"date":"2026-05-28T17:31:01","date_gmt":"2026-05-28T17:31:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=816179"},"modified":"2026-05-28T17:31:01","modified_gmt":"2026-05-28T17:31:01","slug":"duchenne-muscular-dystrophy-market-emerging-as-a-highgrowth-healthcare-investment-space-through-2036-delveinsight-ptc-therapeutics-sarepta-therapeutics-taiho-pharma-regenxbio-fibrogen-roche","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/duchenne-muscular-dystrophy-market-emerging-as-a-highgrowth-healthcare-investment-space-through-2036-delveinsight-ptc-therapeutics-sarepta-therapeutics-taiho-pharma-regenxbio-fibrogen-roche_816179.html","title":{"rendered":"Duchenne Muscular Dystrophy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 \u2013 DelveInsight | PTC Therapeutics, Sarepta Therapeutics, Taiho Pharma, Regenxbio, Fibrogen, Roche"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/05\/1779985458.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Duchenne Muscular Dystrophy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 &ndash; DelveInsight | PTC Therapeutics, Sarepta Therapeutics, Taiho Pharma, Regenxbio, Fibrogen, Roche\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/05\/1779985458.jpg\" alt=\"Duchenne Muscular Dystrophy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 &ndash; DelveInsight | PTC Therapeutics, Sarepta Therapeutics, Taiho Pharma, Regenxbio, Fibrogen, Roche\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Key Duchenne Muscular Dystrophy Companies in the market include &#8211; Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals\/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Roche\/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others.<\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Duchenne Muscular Dystrophy market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2036&Prime;<\/strong> report offers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Duchenne Muscular Dystrophy Market Forecast, Size &amp; Share Analysis Report: <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Duchenne Muscular Dystrophy Market Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The Duchenne Muscular Dystrophy market size was valued at nearly <strong>USD 4,000 million in 2025<\/strong> and is expected to expand at a robust <strong>CAGR of 11%<\/strong> between 2026 and 2036, driven by accelerating progress in therapy development and rising demand for advanced treatment options.<\/p>\n<\/li>\n<li>\n<p><strong>In March 2026, Sarepta Therapeutics<\/strong> provided an update on its ongoing regulatory interactions with the US FDA regarding VYONDYS 53 for the treatment of DMD. Sarepta requested a meeting with the FDA to discuss submitting an sNDA seeking conversion of the accelerated approval of VYONDYS 53 to traditional approvals. This request was supported by data from the ESSENCE confirmatory study; substantial, published real-world evidence supporting treatment; and the favorable safety profiles of both therapies. The Company intends to submit the sNDAs by the end of April.<\/p>\n<\/li>\n<li>\n<p><strong>In March 2026, Regenxbio<\/strong> announced new positive interim data from the Phase I\/II AFFINITY DUCHENNE trial of RGX-202, a potential best-in-class gene therapy for DMD. Trial investigator Carolina Tesi-Rocha, M.D., Clinical Professor, Neurology, Stanford School of Medicine, Stanford Children&#8217;s Health, presented this data, including new functional, safety, biomarker, and cardiac MRI measures, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.<\/p>\n<\/li>\n<li>\n<p>I<strong>n January 2026, Precision BioSciences, Inc. (Nasdaq: DTIL),<\/strong> a clinical-stage gene-editing company leveraging its proprietary ARCUS&reg; platform to advance in vivo gene-editing therapies for diseases with significant unmet need, announced a business update outlining its strategic priorities for 2026. The update highlighted recent advancements across its two lead programs, upcoming clinical milestones, and a solid financial position that supports execution through key value-creating inflection points.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2026, Solid Biosciences (SLDB)<\/strong> shares moved higher on Wednesday after the gene therapy company announced the completion of patient enrollment in its Phase 1\/2 INSPIRE DUCHENNE trial evaluating its lead candidate SGT-003 in children with Duchenne muscular dystrophy, a progressive muscle-wasting disorder. The study had been planned to enroll 50&ndash;60 patients across clinical sites in the United States, Canada, Italy, and the United Kingdom.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2026, Nxera Pharma Co. Ltd (TSE: 4565)<\/strong> announced that it has signed an exclusive licensing agreement with Santhera Pharmaceuticals Holding (SIX: SANN) covering the development, manufacturing, and commercialization of vamorolone for the treatment of Duchenne muscular dystrophy (DMD) in Japan, South Korea, Australia, and New Zealand. Vamorolone is already approved and marketed under the brand name AGAMREE&reg; for DMD, a rare inherited neuromuscular disorder, in the United States, European Union, United Kingdom, and China.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2026, Atossa Therapeutics, Inc. (Nasdaq: ATOS),<\/strong> a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and other areas with significant unmet medical need, announced that the FDA&rsquo;s Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy (DMD).<\/p>\n<\/li>\n<li>\n<p><strong>In October 2025, Regenxbio<\/strong> announced the completion of enrollment in the AFFINITY DUCHENNE pivotal trial of RGX-202, an investigational gene therapy for the treatment of DMD, as well as the successful production of the first batches intended for commercial supply.<\/p>\n<\/li>\n<li>\n<p><strong>In August 2025, The US Food and Drug Administration (FDA)<\/strong> has awarded Breakthrough Therapy designation to delpacibart zotadirsen (del-zota), an investigational therapy for Duchenne muscular dystrophy (DMD) in patients whose mutations are suitable for exon 44 skipping (DMD44). Developed by Avidity Biosciences, del-zota belongs to a new class of RNA-based treatments called Antibody Oligonucleotide Conjugates (AOCs&trade;), which are engineered to enhance targeted delivery and potentially redefine therapeutic approaches for rare genetic disorders.<\/p>\n<\/li>\n<li>\n<p><strong>In July 2025, Sarepta Therapeutics, Inc. (NASDAQ:SRPT),<\/strong> a leading company in precision genetic medicine for rare diseases, released a statement noting that the U.S. Food and Drug Administration (FDA) informally requested the company to voluntarily pause shipments of ELEVIDYS (delandistrogene moxeparvovec), its gene therapy for Duchenne muscular dystrophy, within the U.S. Sarepta stated that it became aware of this potential request earlier in the day through media coverage, at the same time as the general public and patient communities.<\/p>\n<\/li>\n<li>\n<p><strong>In May 2025, Satellos Bioscience&rsquo;s<\/strong> investigational therapy SAT-3247 was found to be safe, well-tolerated, and showed early indications of improved muscle strength in five adults with Duchenne muscular dystrophy (DMD). In the initial part of the Phase 1 trial (NCT06565208), the oral small molecule, administered alongside steroids, demonstrated a favorable safety profile in healthy participants. Additionally, the drug&rsquo;s pharmacokinetics&mdash;how it is absorbed, distributed, metabolized, and excreted&mdash;performed as anticipated in individuals with DMD.<\/p>\n<\/li>\n<li>\n<p><strong>In March 2025, REGENXBIO&rsquo;s<\/strong> investigational gene therapy, RGX-202&mdash;an adeno-associated virus (AAV) vector-based treatment for Duchenne muscular dystrophy (DMD)&mdash;continues to show promising results. Data from two additional patients in the Phase 1\/2 AFFINITY DUCHENNE trial (NCT05693142) reveal that the therapy consistently generates strong levels of microdystrophin expression.<\/p>\n<\/li>\n<li>\n<p><strong>In February 2025, Solid Biosciences<\/strong> reported that its gene therapy candidate, SGT-003, for Duchenne muscular dystrophy (DMD) achieved 110% microdystrophin expression in early clinical testing. The announcement of 90-day biopsy results from the Phase I\/II Inspire DMD trial (NCT06138639) led to a sharp surge in the company&rsquo;s stock, which rose by 78.66%&mdash;jumping from $4.03 on February 14 to $7.20 at market open on February 18. Among the first three of six enrolled patients, the observed gene expression suggests a promising potential to slow disease progression and support muscle function.<\/p>\n<\/li>\n<li>\n<p>The total number of prevalent cases of Duchenne Muscular Dystrophy in the 7MM was around 32,000 in 2025.<\/p>\n<\/li>\n<li>\n<p>The United States encompasses the highest prevalent population of Duchenne Muscular Dystrophy, around 17,500 in 2025.<\/p>\n<\/li>\n<li>\n<p>Among EU4 and the UK, the UK accounts for the highest number of prevalent cases of Duchenne Muscular Dystrophy, whereas Spain accounts for the least number of prevalent cases.<\/p>\n<\/li>\n<li>\n<p>In the US, the age group of 5-9 years accounted for the highest cases in 2025, followed by 10-14 years.<\/p>\n<\/li>\n<li>\n<p>Most cases of Duchenne Muscular Dystrophy involve non-ambulatory individuals.<\/p>\n<\/li>\n<li>\n<p>There are several comorbidities associated with Duchenne Muscular Dystrophy patients. In the United States, the maximum number of DMD patients affected with Scoliosis, followed by Attention-deficit hyperactivity disorder (ADHD) cases, was in 2025.<\/p>\n<\/li>\n<li>\n<p><strong>Key Duchenne Muscular Dystrophy Companies:<\/strong> Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals\/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Roche\/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Duchenne Muscular Dystrophy Therapies:<\/strong> Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others<\/p>\n<\/li>\n<li>\n<p>The Duchenne Muscular Dystrophy epidemiology based on gender analyzed that Duchenne Muscular Dystrophy rarely affects females<\/p>\n<\/li>\n<li>\n<p>In 2023, the age group with the highest number of cases was 5-9, totaling approximately 5,700 cases, followed by the 10-14 age group with around 5,000 cases. Duchenne muscular dystrophy (DMD) is uncommon in individuals above the age of 30.<\/p>\n<\/li>\n<li>\n<p>The Duchenne Muscular Dystrophy market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Duchenne Muscular Dystrophy Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects boys, typically becoming evident in early childhood between the ages of 3 and 5.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Duchenne Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/duchenne-muscular-dystrophy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Duchenne Muscular Dystrophy Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Duchenne Muscular Dystrophy Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Duchenne Muscular Dystrophy Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Duchenne Muscular Dystrophy market report proffers epidemiological analysis for the study period 2022&ndash;2036 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Prevalent Cases of Duchenne Muscular Dystrophy<\/p>\n<\/li>\n<li>\n<p>Age-specific Cases of Duchenne Muscular Dystrophy<\/p>\n<\/li>\n<li>\n<p>Ambulatory and Non-ambulatory Cases of Duchenne Muscular Dystrophy<\/p>\n<\/li>\n<li>\n<p>Mutation-specific Cases of Duchenne Muscular Dystrophy<\/p>\n<\/li>\n<li>\n<p>Associated Comorbidities in Duchenne Muscular Dystrophy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Duchenne Muscular Dystrophy epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/duchenne-muscular-dystrophy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Duchenne Muscular Dystrophy Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Duchenne Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Duchenne Muscular Dystrophy Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Deflazacort (EMFLAZA):<\/strong> PTC Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>Golodirsen (VYONDYS 53):<\/strong> Sarepta Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>EMFLAZA:<\/strong> PTC Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>EXONDYS 51:<\/strong> Sarepta Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>Pizuglanstat (TAS-205):<\/strong> Taiho Pharmaceutical<\/p>\n<\/li>\n<li>\n<p><strong>RGX 202:<\/strong> Regenxbio<\/p>\n<\/li>\n<li>\n<p><strong>Givinostat (ITF2357):<\/strong> Italfarmaco<\/p>\n<\/li>\n<li>\n<p><strong>ATL1102:<\/strong> Antisense Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>SRP-9001:<\/strong> Sarepta Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>Vamorolone:<\/strong> Santhera Pharmaceuticals\/ReveraGen Biopharma<\/p>\n<\/li>\n<li>\n<p><strong>PF06939926:<\/strong> Pfizer<\/p>\n<\/li>\n<li>\n<p><strong>Pamrevlumab:<\/strong> FibroGen<\/p>\n<\/li>\n<li>\n<p><strong>CAP-1002:<\/strong> Capricor Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>Pamrevlumab:<\/strong> Fibrogen<\/p>\n<\/li>\n<li>\n<p><strong>Delandistrogene moxeparvovec:<\/strong> Roche\/Sarepta Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>EDG 5506:<\/strong> Edgewise Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>WVE N531:<\/strong> Wave Life Sciences Ltd<\/p>\n<\/li>\n<li>\n<p><strong>PGN EDO51:<\/strong> PepGen<\/p>\n<\/li>\n<li>\n<p><strong>UX810:<\/strong> Ultragenyx Pharmaceutical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Duchenne Muscular Dystrophy market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/duchenne-muscular-dystrophy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Duchenne Muscular Dystrophy Treatment Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Duchenne Muscular Dystrophy Market Strengths<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The pipeline of DMD is robust with the advent of several potential products in late-stage of clinical development.<\/p>\n<\/li>\n<li>\n<p>Several new therapies have been approved for the treatment of DMD recently, even Japan has witnessed the launch of VILTEPSO now.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Duchenne Muscular Dystrophy Market Opportunities<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Wider commercial opportunity for therapies such as Capricor&rsquo;s CAP-1002 and Antisense&rsquo;s ATL1102, which are specifically focusing on improving upper limb functions in DMD patients and are targeting a much larger patient segment when compared to the Exon-Skipping therapies.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Duchenne Muscular Dystrophy Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Study Period: 2022&ndash;2036<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/p>\n<\/li>\n<li>\n<p>Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals\/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche\/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others<\/p>\n<\/li>\n<li>\n<p>Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others<\/p>\n<\/li>\n<li>\n<p>Duchenne Muscular Dystrophy Therapeutic Assessment: Duchenne Muscular Dystrophy current marketed and Duchenne Muscular Dystrophy emerging therapies<\/p>\n<\/li>\n<li>\n<p>Duchenne Muscular Dystrophy Market Dynamics: Duchenne Muscular Dystrophy market drivers and Duchenne Muscular Dystrophy market barriers<\/p>\n<\/li>\n<li>\n<p>Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/p>\n<\/li>\n<li>\n<p><strong>Duchenne Muscular Dystrophy Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Duchenne Muscular Dystrophy Market Access and Reimbursement <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Duchenne Muscular Dystrophy companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/duchenne-muscular-dystrophy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Duchenne Muscular Dystrophy Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify;\">1. Duchenne Muscular Dystrophy Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Duchenne Muscular Dystrophy<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Duchenne Muscular Dystrophy<\/p>\n<p style=\"text-align: justify;\">4. Duchenne Muscular Dystrophy Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Duchenne Muscular Dystrophy Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Duchenne Muscular Dystrophy Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Duchenne Muscular Dystrophy Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Duchenne Muscular Dystrophy<\/p>\n<p style=\"text-align: justify;\">9. Duchenne Muscular Dystrophy Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Duchenne Muscular Dystrophy Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Duchenne Muscular Dystrophy Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Duchenne Muscular Dystrophy Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Duchenne Muscular Dystrophy Market Analysis (2022&ndash;2036)<\/p>\n<p style=\"text-align: justify;\">14. Duchenne Muscular Dystrophy Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Duchenne Muscular Dystrophy Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Duchenne Muscular Dystrophy Market Barriers<\/p>\n<p style=\"text-align: justify;\">17. Duchenne Muscular Dystrophy Appendix<\/p>\n<p style=\"text-align: justify;\">18. Duchenne Muscular Dystrophy Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=duchenne-muscular-dystrophy-market-emerging-as-a-highgrowth-healthcare-investment-space-through-2036-delveinsight-ptc-therapeutics-sarepta-therapeutics-taiho-pharma-regenxbio-fibrogen-roche\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=duchenne-muscular-dystrophy-market-emerging-as-a-highgrowth-healthcare-investment-space-through-2036-delveinsight-ptc-therapeutics-sarepta-therapeutics-taiho-pharma-regenxbio-fibrogen-roche\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key Duchenne Muscular Dystrophy Companies in the market include &#8211; Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals\/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Roche\/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others. &nbsp; The Duchenne Muscular &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/duchenne-muscular-dystrophy-market-emerging-as-a-highgrowth-healthcare-investment-space-through-2036-delveinsight-ptc-therapeutics-sarepta-therapeutics-taiho-pharma-regenxbio-fibrogen-roche_816179.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-816179","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/816179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=816179"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/816179\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=816179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=816179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=816179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}